Can-Fite BioPharma (CANF) has completed enrolment of the first 247 patients in its pivotal phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis, the company said Monday.

The study has now reached a pre-specified interim stage under a protocol agreed with both the US Food and Drug Administration and the European Medicines Agency, the company said.

Results from the study are expected during Q4 2026 or Q1 2027, the company said.

Shares of the company were up 2.3% in recent premarket trading.